Study finds Lilly's Mounjaro induces greater weight loss compared to Novo Nordisk's Ozempic.

Recently, a study conducted by researchers at a leading university found that Lilly's Mounjaro induces greater weight loss compared to Novo Nordisk's Ozempic. This groundbreaking research sheds light on the potential benefits of Mounjaro in managing weight loss in individuals with obesity.

The study involved a randomized controlled trial with participants who were prescribed either Mounjaro or Ozempic for a period of 12 weeks. The results showed that those who were taking Mounjaro experienced a significantly higher percentage of weight loss compared to those taking Ozempic.

For the study, researchers tracked more than 18,000 overweight and obese people who were prescribed either drug to help control their type 2 diabetes between May 2022 and September 2023.

Both drugs initially were developed as type 2 diabetes medications, but were later approved for use in weight loss.

Results show that both drugs are effective in promoting some weight loss. Nearly 82% of patients taking Mounjaro lost 5% or more of their body weight, compared to nearly 67% of those taking Ozempic, researchers found.

After use of tirzepatide for three months, patients lost an average of 5.9% of their body weight compared to 3.6% for semaglutide. Over a year’s time, those on tirzepatide lost an average of 15.3% of their body weight compared to 8.3% for semaglutide users.

Additionally, tirzepatide patients were much more likely to lose 15% of their body weight than those using semaglutide. While 42% of those on tirzepatide reached the benchmark after one year of treatment, only 18% of those on semaglutide could say the same. 

Lilly’s tirzepatide is the active ingredient found in its diabetes product Mounjaro and its obesity treatment Zepbound, while Novo’s semaglutide is the compound used to make its diabetes blockbuster Ozempic and its obesity follow-on Wegovy.

The Food and Drug Administration approved Ozempic as an insulin-boosting treatment for Type 2 diabetes in 2017. In 2021, the agency added Wegovy, a version approved for weight loss treatment, without obliging insurance companies to cover it.

Novo Nordisk, the Danish company with exclusive rights to sell Ozempic in the U.S. through 2031, has spent millions on advertising and lobbying to expand its market. Its patent monopoly forces patients to pay a monthly premium of $300 to $1,300 out-of-pocket for the drug, which costs about $35 to manufacture.

Along with side effects, people who did not lose weight while taking these medications may be more likely to stop or switch drugs, the researchers say. Discontinuation was common — more than half of patients stopped their treatment before the end of the study — but rates were similar among those taking tirzepatide and those taking semaglutide.

The findings from this study align with clinical trial results, but the study authors note that more research is needed to compare the effects that tirzepatide and semaglutide have on other key health outcomes, such as heart-related events.

 Read more

Sarah H

Also on site :

• Chicago woman’s new Aritzia Super Puff becomes busted. Now she’s de-influencing people who were eyeing the $450 coat: ‘Never an issue with North Face’
• NYC woman gets an email from ‘Skims’ asking for bikini pics. It’s not from Skims: ‘There’s no way y’all are falling for this in 2026’
• ‘Don’t google the Beckhams!’: How to read more, according to Britain’s top authors